PCORI Offers Up to $297.5 Million Through New Funding Opportunities
The Patient-Centered Outcomes Research Institute (PCORI) has opened the application periods for eight funding opportunities that offer up to $297.5 million in total funding. The latest PCORI Funding Announcements (PFAs) include up to $262 million for comparative clinical effectiveness research (CER) studies that help determine which health care options or approaches work best for patients and their caregivers given their particular circumstances.
These first funding opportunities of 2022 advance PCORI’s ambitious three-year funding commitment plan totaling $1.8 billion, which the PCORI Board of Governors approved last year.
Read more about this announcement here.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
